LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis.

    Keske, Şiran / Akyol, Merve / Tanrıöver, Cem / Özlüşen, Batu / Akcan, Rüştü Emre / Güler, Ulaş / Sait, Bilgin / Kaçmaz, Bahar / Gönen, Mehmet / Ergönül, Önder

    Infection

    2023  Volume 51, Issue 6, Page(s) 1619–1628

    Abstract: Purpose: Tocilizumab, a monoclonal IL-6 receptor blocker, is an effective agent for severe-to-critical cases of COVID-19; however, its target patients for the optimum use need to be detailed. We performed a systematic review and meta-analysis to define ... ...

    Abstract Purpose: Tocilizumab, a monoclonal IL-6 receptor blocker, is an effective agent for severe-to-critical cases of COVID-19; however, its target patients for the optimum use need to be detailed. We performed a systematic review and meta-analysis to define its effect among severely ill but non-intubated cases with COVID-19.
    Methods: We searched PubMed, Scopus, Web of Science, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Medrxiv, and Biorxiv until February 13, 2022, for non-intubated cases, and included randomized-controlled trials (RCT) based on bias assessment. The primary outcomes were the requirement of invasive mechanical ventilation and mortality. Random effect and fixed-effect models were used. The heterogeneity was measured using the χ
    Results: Among 261 articles, 11 RCTs were included. The pooled analysis of the 11 RCTs demonstrated that the rate of mortality was significantly lower in the tocilizumab group than in the control group (20.0% and 24.2%, OR: 0.84, 95% CI 0.73-0.96, and heterogeneity I
    Conclusion: Among non-intubated severe COVID-19 cases, tocilizumab reduces the risk of invasive mechanical ventilation and mortality compared to standard-of-care treatment.
    MeSH term(s) Humans ; COVID-19 ; COVID-19 Drug Treatment ; Antibodies, Monoclonal, Humanized/therapeutic use ; Respiration, Artificial
    Chemical Substances tocilizumab (I031V2H011) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-05-10
    Publishing country Germany
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 185104-4
    ISSN 1439-0973 ; 0300-8126 ; 0173-2129
    ISSN (online) 1439-0973
    ISSN 0300-8126 ; 0173-2129
    DOI 10.1007/s15010-023-02047-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 881: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 528: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Effectiveness of favipiravir in COVID-19: a live systematic review.

    Özlüşen, Batu / Kozan, Şima / Akcan, Rüştü Emre / Kalender, Mekselina / Yaprak, Doğukan / Peltek, İbrahim Batuhan / Keske, Şiran / Gönen, Mehmet / Ergönül, Önder

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2021  Volume 40, Issue 12, Page(s) 2575–2583

    Abstract: We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on the fatality and the requirement of mechanical ventilation for the treatment of moderate to severe COVID-19 patients. We searched available literature and reported  ...

    Abstract We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on the fatality and the requirement of mechanical ventilation for the treatment of moderate to severe COVID-19 patients. We searched available literature and reported it by using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Until June 1, 2021, we searched PubMed, bioRxiv, medRxiv, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar by using the keywords "Favipiravir" and terms synonymous with COVID-19. Studies for Favipiravir treatment compared to standard of care among moderate and severe COVID-19 patients were included. Risk of bias assessment was performed using Revised Cochrane risk of bias tool for randomized trials (RoB 2) and ROBINS-I assessment tool for non-randomized studies. We defined the outcome measures as fatality and requirement for mechanical ventilation. A total of 2702 studies were identified and 12 clinical trials with 1636 patients were analyzed. Nine out of 12 studies were randomized controlled trials. Among the randomized studies, one study has low risk of bias, six studies have moderate risk of bias, and 2 studies have high risk of bias. Observational studies were identified as having moderate risk of bias and non-randomized study was found to have serious risk of bias. Our meta-analysis did not reveal any significant difference between the intervention and the comparator on fatality rate (OR 1.11, 95% CI 0.64-1.94) and mechanical ventilation requirement (OR 0.50, 95% CI 0.13-1.95). There is no significant difference in fatality rate and mechanical ventilation requirement between Favipiravir treatment and the standard of care in moderate and severe COVID-19 patients.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amides/administration & dosage ; Amides/adverse effects ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/therapy ; COVID-19/virology ; Female ; Humans ; Male ; Middle Aged ; Observational Studies as Topic ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Randomized Controlled Trials as Topic ; Respiration, Artificial ; SARS-CoV-2/drug effects ; SARS-CoV-2/genetics ; SARS-CoV-2/physiology ; Young Adult
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2021-08-04
    Publishing country Germany
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-021-04307-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1732: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

    Demirlenk, Yusuf Mert / Gücer, Lal Sude / Uçku, Duygu / Tanrıöver, Cem / Akyol, Merve / Kalay, Zeynepgül / Barçın, Erinç / Akcan, Rüştü Emre / Can, Füsun / Gönen, Mehmet / Ergönül, Önder

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2022  Volume 41, Issue 5, Page(s) 761–769

    Abstract: We aimed to describe the effect of aminoglycosides and tigecycline to reduce the mortality in colistin- and carbapenem-resistant Klebsiella pneumoniae (ColR-CR-Kp) infections. We included the studies with defined outcomes after active or non-active ... ...

    Abstract We aimed to describe the effect of aminoglycosides and tigecycline to reduce the mortality in colistin- and carbapenem-resistant Klebsiella pneumoniae (ColR-CR-Kp) infections. We included the studies with defined outcomes after active or non-active antibiotic treatment of ColR-CR-Kp infections. The active treatment was defined as adequate antibiotic use for at least 3 days (72 h) after the diagnosis of ColR-CR-Kp infection by culture. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the checklist of PRISMA 2020 was applied. Crude and adjusted odds ratios (OR) with 95% confidence interval (CI) were calculated and pooled in the random effects model. Adding aminoglycosides to the existing treatment regimen reduced overall mortality significantly (OR 0.34, 95% CI 0.20-0.58). Overall mortality was 34% in patients treated with aminoglycoside-combined regimens and was 60% in patients treated with non-aminoglycoside regimens. Treatment with tigecycline is not found to reduce mortality (OR: 0.76, 95% CI: 0.47-1.23). Our results suggest that aminoglycoside addition to the existing regimen of colistin- and carbapenem-resistant Klebsiella pneumoniae infections reduces mortality significantly.
    MeSH term(s) Aminoglycosides/pharmacology ; Aminoglycosides/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Carbapenem-Resistant Enterobacteriaceae ; Carbapenems/pharmacology ; Carbapenems/therapeutic use ; Colistin/pharmacology ; Colistin/therapeutic use ; Humans ; Klebsiella Infections/microbiology ; Klebsiella pneumoniae ; Microbial Sensitivity Tests ; Sepsis/drug therapy ; Tigecycline/pharmacology ; Tigecycline/therapeutic use
    Chemical Substances Aminoglycosides ; Anti-Bacterial Agents ; Carbapenems ; Tigecycline (70JE2N95KR) ; Colistin (Z67X93HJG1)
    Language English
    Publishing date 2022-03-18
    Publishing country Germany
    Document type Journal Article ; Meta-Analysis
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-022-04429-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1732: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top